Biotechnology

Monday Jun 24, 2024 - 10:17 am

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Welcomes Ryan Garcia as Brand Ambassador

Safety Shot (NASDAQ: SHOT) today announced a partnership with professional boxer, Ryan Garcia, as a brand ambassador. Garcia began his professional career at 17-years-old and holds a 25-1 victory record, 20 of those wins resulting in knockouts. Garcia’s dedicated followers are integrated with all components of his career, and having the support and loyalty of these fans will largely bolster brand awareness and recognition for…

Friday Jun 21, 2024 - 3:13 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Presents New Preliminary Data Demonstrating Potential of CNM-Au8(R) as Treatment for Rett Syndrome

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene today announced that Karen Ho, Ph.D., the company’s vice president of translational medicine, presented new, preliminary data demonstrating the potential of…

Thursday Jun 20, 2024 - 12:09 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) TRACER 1000(TM) Receives ‘Approved’ Status on Air Cargo Security Technology List

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the U.S. Transportation Security Administration (“TSA”) has approved the TRACER 1000(TM) for the Air Cargo Security Technology List (“ACSTL”) following thorough assessment by the TSA QG2 Technical Review Panel (“TRP”). Following the approval, regulated parties in the U.S., such as the air cargo market, which are required to use the ACSTL,…

Thursday Jun 20, 2024 - 10:03 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application (“NDA”) filing. According to the update, Nutriband is currently working…

Thursday Jun 20, 2024 - 9:15 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, presented new long-term CNM-Au8 treatment results for survival and neurofilament light (“NfL”) levels from the HEALEY ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS…

Tuesday Jun 18, 2024 - 12:09 pm

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) to Host Business and Financial Update Teleconference

Pressure BioSciences (OTCQB: PBIO), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables and specialty process development and testing services across global industries, today announced that it will host a teleconference to update investors and other stakeholders on various business and financial topics. The teleconference , scheduled to take place starting at 4:30 p.m. ET on Thursday, June 20, 2024, will…

Tuesday Jun 18, 2024 - 11:50 am

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, will be featured during an upcoming fireside chat hosted by Ascendiant Capital Markets. According to the announcement, IGC Pharma CEO Ram Mukunda and CCO Claudia Grimaldi will be presenting during the event, which is slated to begin at 12 p.m. ET on June 27, 2024. During the presentation, the IGC Pharma management team members are expected to…

Monday Jun 17, 2024 - 9:05 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and…

Thursday Jun 13, 2024 - 1:49 pm

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Schedules Business, Financial Update

Pressure BioSciences (OTCQB: PBIO) is a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables and specialty process development and testing services across global industries. The company today announced that it will host a teleconference on Wednesday, June 19, 2024, at 4:30 p.m. ET to update investors and other stakeholders on various business and financial topics. The company will discuss FY 2023…

Thursday Jun 13, 2024 - 1:13 pm

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC…

Thursday Jun 13, 2024 - 12:09 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step paves the way for potential commercial availability in the U.S.…

Thursday Jun 13, 2024 - 10:13 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for converting EIB's loan of approximately $27.6 million into equity in the form…

Wednesday Jun 12, 2024 - 10:45 am

InvestorNewsBreaks – HealthLynked Corp. (HLYK) Unveils New Online Medical Record Request Form, Is Featured in Latest Episode of Bell2Bell Podcast

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has unveiled a new online medical record request form, which is integrated with DocuSign. According to the announcement, patients can now seamlessly request their medical records with only a few clicks, and the records are automatically added to the patients' HealthLynked Network profile. The integration with DocuSign, a pioneer in electronic-signature technology, makes the request…

Wednesday Jun 12, 2024 - 9:46 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update

Vistagen Therapeutics (NASDAQ: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting financial results for the fiscal year ended March 31, 2024; the report also included a corporate update. Highlights of the report included that Vistagen’s registration-directed fasedienol PALISADE phase 3 program for the acute treatment…

Tuesday Jun 11, 2024 - 2:24 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal EmergingGrowth.com. Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Clene’s President and CEO Rob Etherington…

Tuesday Jun 11, 2024 - 1:12 pm

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces CEO Participation in Emerging Growth Conference, Completion of Investigator Meeting for Phase 2b Clinical Trial

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is participating in this week’s Emerging Growth Virtual Conference. The agenda for the event indicates Longeveron CEO and director Mohamed Wa’el Hashad will be speaking tomorrow at 1:45 p.m. ET; the two-day conference is slated for June 12–13. In addition, Longeveron has successfully completed an investigator meeting…

Monday Jun 10, 2024 - 11:53 am

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Publication of Key Study in European Journal

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has published a significant research study. The company announced that the study, titled “A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,” was published in the “European Society of Medicine” journal. According to the announcement, the study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of…

Friday Jun 07, 2024 - 10:48 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call

Vistagen (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, plans to host a conference call and webcast on Tuesday, June 11, 2024, at 2 p.m. PT (5 p.m. ET). During the conference call, the company will report results for its fiscal year 2024 ended March 31, 2024, and provide a corporate update. Interested parties…

Friday Jun 07, 2024 - 10:03 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, the offering was comprised of 917,432 shares of common stock (or common stock equivalents in lieu thereof) offered at a purchase price of $2.18 per share. The company also announced…

Wednesday Jun 05, 2024 - 3:07 pm

InvestorNewsBreaks — Astiva Health Inc. to Host Summer Gala

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, today announced the Astiva Health Summer Gala, to be held at its headquarters in Orange, California. The event marks a significant milestone for the company and is slated to take place from 5 p.m. to 10 p.m. PT on June 29, 2024. The gala will feature live…

Wednesday Jun 05, 2024 - 2:56 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Strategic Reorganization, CCO Appointment

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, today announced a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. The move reflects Dario’s commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability. To achieve this goal, DarioHealth is implementing a new organizational model. The president…

Wednesday Jun 05, 2024 - 11:14 am

InvestorNewsBreaks – HealthLynked Corp. (HLYK) Receives $1M from CEO to Support Company’s Efforts to ‘Lead the Way’ to More Efficient Healthcare System

HealthLynked (OTCQB: HLYK), a leader in personalized healthcare and patient-centric services, has received $1 million in financing from CEO Dr. Michael Dent, which will provide additional capital so the company can expand its offerings and accelerate its growth. A visionary in the healthcare industry, Dent has been at the helm of HealthLynked as it has developed services designed to enhance the patient experience and improve…

Wednesday Jun 05, 2024 - 9:56 am

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company’s lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the…

Tuesday Jun 04, 2024 - 9:41 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT), Mr. Checkout Announce Partnership to Expand Nationwide Distribution through Independent Retailers

Safety Shot (NASDAQ: SHOT), a wellness and dietary supplement company, is expanding its distribution footprint through a strategic partnership with Mr. Checkout, a national network of independent distributors, full-line grocery distributors and wagon-jobbers. Calling the collaboration a “significant milestone” in the company’s mission to provide a revolutionary solution for responsible alcohol consumption to the masses, the company noted that the partnership will help to introduce…

Monday Jun 03, 2024 - 2:20 pm

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Launches New Four-Ounce Bottles for Flagship Product

Safety Shot (NASDAQ: SHOT), a wellness and dietary supplement company, has unveiled new bottling for its revolutionary new formula. A first-of-its-kind functional beverage, Safety Shot contains essential B vitamins, antioxidants, electrolytes and nootropics designed to boost mental clarity, energy and overall mood. The product is now available in convenient, on-the-go four-ounce bottles, making it more portable for enhanced accessibility and convenience. Safety Shot is the…

Monday Jun 03, 2024 - 10:48 am

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Launches New Business, Eyes Opportunity in Contract Manufacturing

Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-foot, state-of-the-art Good Manufacturing Practice (“GMP”) facility. In addition, the company announced the initiation of work under its first manufacturing services contract with Secretome Therapeutics, a biotechnology company developing first-in-class…

Monday Jun 03, 2024 - 9:33 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 p.m. ET on June 4, 2024. According to the update, beginning on June 5, 2024, the company’s common stock will continue to trade on the Nasdaq…

Friday May 31, 2024 - 3:37 pm

InvestorNewsBreaks – Biomerica Inc. (NASDAQ: BMRA) Announces Agreement in $5.5M At-the-Market Offering

Biomerica (NASDAQ: BMRA), a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agreement is related to BMRA common stock shares. The company filed a prospectus supplement on May 10, 2024. EF Hutton is serving as sales…

Friday May 31, 2024 - 2:06 pm

InvestorNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that…

Wednesday May 29, 2024 - 11:54 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company has announced that its management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference slated to take place in New York City on June 5 and 6, 2024. Vistagen’s Chief Executive Officer Shawn Singh will participate in…

Wednesday May 29, 2024 - 10:30 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled “Novel AI Driven Insights to Guide Early Drug Discovery,” is…

Wednesday May 29, 2024 - 9:43 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval,…

Tuesday May 28, 2024 - 1:11 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1

IGC Pharma (NYSE American: IGC) today announced patient enrollment at Neurostudies Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for agitation in Alzheimer’s disease. According to the announcement, IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties and an inflammasome inhibitor, to treat agitation in dementia due…

Tuesday May 28, 2024 - 11:55 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced several key updates on its National Institutes of Health (“NIH”) funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8® compassionate use (“EAP”) in ALS. Late last year, in…

Tuesday May 28, 2024 - 10:38 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Positive Results from Ovarian Cancer Study

Predictive Oncology (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago. “We would like to thank Brian Orr, MD, lead…

Tuesday May 28, 2024 - 9:09 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effective May 22, 2024, outlines IR Agency’s responsibilities to communicate information about FSD Pharma to the financial community. That information could include company…

Thursday May 23, 2024 - 9:46 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is scheduled to present two posters at this month’s American Society of Clinical Psychopharmacology Conference. The conference is scheduled for May 28–31, 2024, in Miami Beach, Florida. The posters will feature fasedienol, Vistagen’s investigational pherine candidate, which is currently in phase 3…

Wednesday May 22, 2024 - 3:24 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity…

Wednesday May 22, 2024 - 2:10 pm

InvestorNewsBreaks – SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology

SOHM (OTC: SHMN), a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The revolutionary new ABBIE system, due…

Wednesday May 22, 2024 - 1:49 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments

PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. "The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica responded to this call for help by…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions